Login to Your Account



Behind the Partnering Curtain

Avaxia's Barbara Fox Stays on the Run at BIO 2013

By Marie Powers
Staff Writer

Monday, April 29, 2013

CHICAGO – For Avaxia Biologics Inc., the decision to attend BIO 2013 was a no-brainer. The Lexington, Mass.-based company is in the middle of a Phase Ib study of lead compound AVX-470, an orally administered anti-TNF polyclonal antibody, in ulcerative colitis (UC).

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription